A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 4

Conditions: Adenomatous Polyposis Coli

Treatments: Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks; Drug: Comparator: placebo / Duration of Treatment: 24 weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00140894

2005_052

0966-205

Details and patient eligibility

About

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Males or females at least 18 years of age with familial adenomatous polyposis.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind